Fulcrum Therapeutics, Inc.’s Current Ratio at a glance
Fulcrum Therapeutics, Inc. reports current ratio of 22.63 for Dec 2024. The prior period recorded 17.71 (Dec 2023). Year over year the metric moved +4.92 (+27.8%). The rolling three-period average stands at 17.58. Data last refreshed Dec 7, 2025, 2:47 AM.
Latest reading
22.63 · Dec 2024
YoY movement
+4.92 (+27.8%)
Rolling average
17.58
Current Current Ratio
22.63
+4.92
+27.8%
Rolling average
17.58
Latest Value
22.63
Dec 2024
YoY Change
+4.92
Absolute
YoY Change %
+27.8%
Rate of change
3-Period Avg
17.58
Smoothed
Narrative signal
Fulcrum Therapeutics, Inc.’s current ratio stands at 22.63 for Dec 2024. Year-over-year, the metric shifted by +4.92, translating into a +27.8% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How current ratio shapes Fulcrum Therapeutics, Inc.'s story
As of Dec 2024, Fulcrum Therapeutics, Inc. reports current ratio of 22.63. Monitor liquidity coverage to understand a company’s ability to meet near-term obligations from working capital.
Reading the current ratio
Ratios above 1.0 indicate more current assets than liabilities. Very high ratios may signal idle capital.
Use with other liquidity metrics
Pair current ratio with quick ratio and cash flow to assess how liquid assets convert to cash.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
98%
Operating Margin
-27.4%
Net Profit Margin
-12.2%
Return on Equity
-4%
Return on Assets
-3.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Fulcrum Therapeutics, Inc. (FULC) FAQs
Answers tailored to Fulcrum Therapeutics, Inc.’s current ratio profile using the latest Financial Modeling Prep data.
What is Fulcrum Therapeutics, Inc.'s current current ratio?
As of Dec 2024, Fulcrum Therapeutics, Inc. reports current ratio of 22.63. This reading reflects the latest filings and price data for FULC.
How is Fulcrum Therapeutics, Inc.'s current ratio trending year over year?
Year-over-year, the figure shifts by +4.92 (+27.8%). Pair this context with revenue growth and free cash flow signals to gauge momentum for FULC.
Why does current ratio matter for Fulcrum Therapeutics, Inc.?
The current ratio compares current assets to current liabilities to assess short-term liquidity. For Fulcrum Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Fulcrum Therapeutics, Inc.'s current ratio above its recent average?
Fulcrum Therapeutics, Inc.'s rolling three-period average sits at 17.58. Comparing the latest reading of 22.63 to that baseline highlights whether momentum is building or fading for FULC.
How frequently is Fulcrum Therapeutics, Inc.'s current ratio refreshed?
Data for FULC was last refreshed on Dec 7, 2025, 2:47 AM and updates automatically every 24 hours, keeping your valuation inputs current.